Canada Spends Logo

Explore our Budget 2026 analysis

Contribution: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

11281232 Canada Inc.

$375,070.00

ADAPT: Accessible Diagnostics for Aging-in-Place Testing

FY 2025-26 · 2026-02-17

Summary
Through ADAPT: Accessible Diagnostics for Aging-in-Place Testing will be completed in a collaboration betweenLFAnt Medical and the National Research Council of Canada (NRC) to improve access to health screening solutions for older Canadians.The project focuses on the verification of the ADAPT platform for the early detection of urinary biomarkers for chronic kidney disease (CKD), which poses disproportionate and preventable health risks among older adults. The ADAPT platform combines the NRC’s latest innovations in microfluidics-powered technologies with LFAnt medical’s next generation electromagnetic biosensors. It features a reusable reader and disposable test cartridges designed for use by minimally trained operators in community-based healthcare settings such as nursing homes and other long-term care facilities. The ADAPT platform is set to transform the paradigm of disease detection and monitoring and promote healthy aging among older Canadians.
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
708315684
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions

As published

Agreement End Date
2028-03-31
Agreement Number
1039268
Agreement Start Date
2026-02-17
Agreement Title
ADAPT: Accessible Diagnostics for Aging-in-Place Testing
Agreement Title (French)
Diagnostics accessibles pour tests à domicile de personnes vieillissantes
Agreement Type
Contribution
Agreement Value
$375,070.00
Amendment Number
0
Description
Through ADAPT: Accessible Diagnostics for Aging-in-Place Testing will be completed in a collaboration betweenLFAnt Medical and the National Research Council of Canada (NRC) to improve access to health screening solutions for older Canadians.The project focuses on the verification of the ADAPT platform for the early detection of urinary biomarkers for chronic kidney disease (CKD), which poses disproportionate and preventable health risks among older adults. The ADAPT platform combines the NRC’s latest innovations in microfluidics-powered technologies with LFAnt medical’s next generation electromagnetic biosensors. It features a reusable reader and disposable test cartridges designed for use by minimally trained operators in community-based healthcare settings such as nursing homes and other long-term care facilities. The ADAPT platform is set to transform the paradigm of disease detection and monitoring and promote healthy aging among older Canadians.
Description (French)
Grâce à la plateforme de diagnostics accessibles pour tests à domicile de personnes vieillissantes, ADAPT, un projet mené en collaboration entre LFAnt Medical et le CNRC entend améliorer l’accès aux solutions de contrôle de santé pour les personnes âgées au Canada. Le projet se concentre sur la vérification de la plateforme ADAPT pour la détection précoce des biomarqueurs urinaires de la maladie rénale chronique (MRC), qui présente des risques disproportionnés et évitables pour la santé des personnes âgées. La plateforme ADAPT allie les dernières innovations du CNRC en technologies microfluidiques avec les biocapteurs électromagnétiques de nouvelle génération de LFAnt Medical. Elle comprend un lecteur réutilisable et des cartouches de test jetables conçues pour être utilisées par des personnes ayant des compétences de base dans des établissements de soins de santé communautaires, tels que les maisons de retraite et autres établissements de soins de longue durée. La plateforme ADAPT est appelée à transformer le paradigme de la détection et de la surveillance des maladies et à promouvoir le vieillissement en bonne santé chez les personnes âgées au Canada.
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Toronto Centre
Federal Riding (French)
Toronto-Centre
Federal Riding Number
35109
NAICS Code
541710 - R&D in the physical, engineering and life sciences
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
708315684
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
11281232 Canada Inc.
Recipient Postal Code
M5A 1M3
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2025-2026-Q4-1039268
11281232 Canada Inc. - $375,070 Contribution (2025-26) | Canada Spends